stockrowTrulieve Cannabis Corp.
TRLV Healthcare Drug Manufacturers Specialty & Generic
Trulieve Cannabis Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- −20.1%
- EPS
- −2,391.1%
- Free cash flow
- +24.5%
- Total debt
- −37.0%
Quarter to September 2026, against a year earlier
Follow TRLV
Alert me
Trulieve Cannabis Corp. (TRLV) Free cash flow
Trulieve Cannabis Corp.'s free cash flow for fiscal 2025 was $212.3M, up 71.5% from $123.8M in fiscal 2024. Over the twelve months to 30 September 2026 it was $242.5M. Over the past ten years it has ranged from −$232.7M (fiscal 2021) to $212.3M (fiscal 2025) — the current reading is the highest in ten years. Trulieve Cannabis Corp. ranks 12th of 84 Drug Manufacturers Specialty & Generic companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $212.3M | 71.47% |
| FY2024 | $123.8M | (17.99%) |
| FY2023 | $151.0M | — |
| FY2022 | −$160.9M | — |
| FY2021 | −$232.7M | — |
| FY2020 | −$42.3M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $74.4M | 131.62% |
| Jun 2026 | $32.1M | (23.90%) |
| Mar 2026 | $42.2M | (18.98%) |
| Dec 2025 | $52.1M | (12.83%) |
| 19 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| BCRX BioCryst Pharmaceuticals, Inc. compare | $366.4M |
| TRLV Trulieve Cannabis Corp. | $242.5M |
| PBH Prestige Consumer Healthcare Inc. compare | $214.2M |
| ANIP ANI Pharmaceuticals, Inc. compare | $205.3M |
| PRGO Perrigo Company plc compare | $168.2M |
| XERS Xeris Biopharma Holdings, Inc. compare | $73.6M |
| RGC Regencell Bioscience Holdings Limited compare | −$14.7M |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | −$171.8M |
| ALVO Alvotech compare | −$211.7M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on TRLV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement